




DuTOC

Annual report



DUTOC

... Dutch Thoracic Oncology Cohort ...

Content

1.	Introduction	3
2.	Overview prospective Dutch Thoracic Oncology Cohort (DuTOC)	4
2.1.	Initial approval and inclusion	4
3.	Data from the Netherlands Cancer Registry	4
4.	Future prospects	5
5.	Contact details	6
5.1.	Website	6
5.2.	Organization	6
5.3.	Scientific committee.....	6
5.4.	Collaboration.....	6
6.	Appendix.....	8
6.1.	Studies embedded in DuTOC infrastructure	8
6.2.	Publications	9
6.3.	Presentations	9

1. Introduction

We are pleased to present the first annual report of the Dutch Thoracic Oncology Cohort (DuTOC). Following preparatory work and with the support of the OncoCode Accelerator Grant, DuTOC was launched in the autumn of 2024.

In this report, we are proud to share with you DuTOC's achievements so far. We hope and expect that DuTOC will evolve into a trusted and impactful partner in research and quality control for the Dutch lung cancer community.

None of this would have been possible without the commitment and enthusiasm of many people. We would like to sincerely thank all participating patients, healthcare professionals and all our partners for their collaborations. DuTOC is a joint effort for all involved.

We hope you enjoy reading this report, and we look forward to continuing this journey together as we further develop and strengthen DuTOC in the years ahead.

On behalf of the sponsor *Stichting NVALT studies*,

Wouter de Jong, principal investigator

Femke van der Velde, project manager

2. Overview Dutch Thoracic Oncology Cohort (DuTOC)

The Dutch Thoracic Oncology Cohort (DuTOC) is a prospective observational cohort study with stichting NVALT-studies as sponsor. DuTOC aims to collect clinical data, patient reported outcomes, and biomaterials from patients who have been diagnosed with a primary thoracic malignancy in one of the participating hospitals in the Netherlands. Within this annual report we provide a summary of the achievements from 2025 and early 2026.

2.1. Initial approval and inclusion

The initial submission was provided to the METC NedMec on 24Apr2025, whereafter approval was received on 24Jul2025. The first participant was enrolled within UMCU on 18Aug2025.

As of 14Jul2026, the DuTOC consists of:

- **12** hospitals open for inclusion
- **249** participants enrolled

The inclusion of participants (Figure 1) aligns with the activation dates of the participating hospitals. Most initiation visits took place at the end of 2025 and the beginning of 2026, after which the number of enrolled participants gradually increased.




Figure 1_Number of included participants per month.

These numbers include passed away participants and excluding participants that fully withdraw their consent

3. Data from the Netherlands Cancer Registry

The DuTOC receives data from the Netherlands Cancer Registry (NCR). These data are prospectively and reliably collected from medical charts and pathology reports. First NCR registration will be 6 months after the onset date. One year after onset, the registration is completed if it has not already been done.

Of the 209 participants included in DuTOC on 07May2026, the registration of 41 were not yet completed in the NCR, 1 patient was not part of the NCR and 2 patients were excluded because at time of linking, the diagnosis was not yet confirmed within the NCR.

The remaining 165 participants were linked.

4. Future prospects

For 2026 we expect the following activities:

- Expansion of cohort, scale up with at least 12 hospitals with the first METC amendment
- Starting with sub-studies
 - 5 participating sub-studies live
- Inclusion of >30% of new patients with lung cancer at the participating hospitals
- e-Consent option
- Aim for financial sustainability.

5. Contact details

5.1. Website

www.dutoc.nl

5.2. Organization

DuTOC consists of a board which includes stichting NVALT-studies (sponsor) and the day-to-day management DuTOC board consisting of Principal Investigator dr. W. de Jong and Project Manager F. van der Velde.

The DuTOC board receives advice from the scientific committee about scientific and organisational issues, data governance and performs a scientific review on data requests and substudies. A non-public protocol on scientific and data regulations has been approved.

5.3. Scientific committee

The Scientific Committee consists of:

- | | |
|-----------------------|---------------------------------|
| • W. de Jong | Pulmonologist, DuTOC PI (Chair) |
| • F. van der Velde | DuTOC PM (Secretary) |
| • L. Hendriks | Pulmonologist, Chair sNs |
| • A. Keijser | cPM sNs |
| • M. van den Heuvel | Pulmonologist, Treasurer sNs |
| • D. Dumoulin | Pulmonologist, Secretary sNs |
| • K. Hartemink | Lung surgeon, Chair DTG |
| • J. von der Thüsen | Pathologist |
| • C. van der Leest | Pulmonologist, DICA |
| • E. van de Garde | Pharmacist |
| • A. Eijkelboom | IKNL |
| • J. Verhoeff | Radiotherapist |
| • E. van Werkhoven | Statistician |
| • F. Mohamed Hoessein | Radiologist |
| • L. Barberio | Longkanker Nederland |
| • I. Walraven | Profiel |
| • A. van der Wekken | Pulmonologist |

5.4. Collaboration

DuTOC has a collaboration with a broad variety of parties and organisations, consisting of:



Incl. Other cohorts (e.g. PLCRC, ProBCI, PACAP, POCOP, Force, DBCC, Marathon)

profiel

**Vereniging
Innovatieve
Geneesmiddelen**



And a special thanks to the sponsoring parties:



6. Appendix

6.1. Studies embedded in DuTOC infrastructure

Currently only studies in preparation.

Study name	Description	Start date	Sample size	Number of included participants since xx

6.2. Publications

Website: dutoc.nl

Short patient information movie

- *DuTOC: een grote vijver om in te vissen* – Oncologie Vandaag (December, 2025)
- *Nieuw landelijk platform voor onderzoek longkanker* – Longkanker Nederland (November, 2025)
- *DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies* – Lung Cancer (August, 2025)
- *Het Dutch Thoracic Oncology Cohort: “Een mooie kapstok voor allerlei substudies”* – MedNet (May, 2025)

6.3. Presentations

- sNs studiedag_Nov2025
- IKNL_Sept2025
- Santeon meeting_Jan2026
- DTG meetings